Expression of p53, Glutathione S -Transferase- , and Bcl-2 Proteins and Benefit From Adjuvant Radiotherapy in Breast Cancer

Abstract

Our study provides indirect evidence of a benefit from radiation therapy in preventing local breast cancer relapse, particularly among node-negative patients with tumors that express elevated levels of the p53 or GST-pi proteins or that express little or no Bcl-2 protein.

Association between GSTP1 Genotypes and Hormone Receptor Phenotype in Invasive Ductal Carcinomas of Breast

“…Similar relation was found in tumors with heterozygote genotype of GSTP1 regarding positive and negative IHC PR stain and tumor grade. These results are consistent with studies that showed an inverse correlation with ER (Gilbert et al, 1993;Silvestrini et al, 1997;MoureauZabotto et al, 2006;Rodríguez et al, 2014), and the two studies of Pongtheerat and colleagues which reported GSTP1 polymorphism was unrelated to increased risk of breast cancer, but found an inverse relationship between GSTP1 genotype and progesterone receptor protein (Pongtheerat et al, 2009;Pongtheerat et al, 2011), and positive correlation with better tumor differentiation and grade (Cairns et al, 1992;Haas et al, 2006). The findings of the current study are in harmony with the report of Ge et al who reported that GSTP1 105Val allele carriers were more liable to have a higher histological grade tumor and negative ER stain than Ile/Ile allele carriers (Ge et al, 2013).…”

“…However, to date the results are still somewhat controversial and may vary from population to population. (Gilbert et al, 1993;Silvestrini et al, 1997;Buser et al, 1997;Helzlsouer et al, 1998;Millikan et al, 2000;Mitrunen et al, 2001;Gudmundsdottir et al, 2001;Huang et al, 2003;Egan et al, 2004;Sreenath et al, 2005;Moureau-Zabotto et al, 2006;Unlu et al, 2008;Saxena et al, 2009;Arun et al, 2010;Pongtheerat et al, 2011;Zhang et al, 2011;Ramalhinho et al, 2011;Aguiar et al, 2012;Ramalhinho et al, 2012;Saxena et al, 2013;Khabaz, 2014;Rodríguez et al, 2014).…”

“…Many previous studies revealed GSTP1 polymorphism has no correlation with clinical and pathologic tumor characteristics (Buser et al, 1997;Huang et al, 2003) only a few studies showed an inverse correlation with ER (Gilbert et al, 1993;Silvestrini et al, 1997;Moureau-Zabotto et al, 2006). Furthermore, two studies of Pongtheerat and colleagues reported that GSTP1 polymorphism was unrelated to increased risk of breast cancer, but found an inverse relationship between GSTP1 genotype and progesterone receptor protein (Pongtheerat et al, 2009;Pongtheerat et al, 2011), and positive correlation with better tumor differentiation and grade (Cairns et al, 1992;Haas et al, 2006).…”

“…Many studies investigated the possible link between GSTP1 polymorphisms and breast cancer risk, and have shown conflicting results (Gilbert et al, 1993;Silvestrini et al, 1997;Buser et al, 1997;Helzlsouer et al, 1998;Millikan et al, 2000;Mitrunen et al, 2001;Gudmundsdottir et al, 2001;Huang et al, 2003;Egan et al, 2004;Sreenath et al, 2005;Moureau-Zabotto et al, 2006;Unlu et al, 2008;Saxena et al, 2009;Arun et al, 2010;Pongtheerat et al, 2011;Zhang et al, 2011;Ramalhinho et al, 2011;Aguiar et al, 2012;Ramalhinho et al, 2012;Khabaz, 2014;Rodríguez et al, 2014). Many previous studies revealed GSTP1 polymorphism has no correlation with clinical and pathologic tumor characteristics (Buser et al, 1997;Huang et al, 2003) only a few studies showed an inverse correlation with ER (Gilbert et al, 1993;Silvestrini et al, 1997;Moureau-Zabotto et al, 2006).…”

Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients

“…However, results from immunhistochemical studies do not indicate that normal expression of p53 is a necessity for response to tamoxifen (14 Á/17). Altered p53 has been reported to predict good response to postoperative radiotherapy in breast cancer in preventing local recurrence (18) and death from breast cancer (19), although several studies have reported that p53 accumulation is associated with an increased risk of local relapse (20 Á/23).…”